This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Research Highlights: Edoxaban, a medication taken orally to prevent bloodclots from forming, was found to be as effective and safe for stroke and bloodclot prevention in patients after heartvalve replacement surgery as warfarin, the current.
Some patients who receive heartvalve implants develop dangerous bloodclots, and researchers from the University of Waterloo contributed to an international collaboration that reduces the risk.
The research is funded by a four-year, $7.8 million grant awarded to Georgia Tech by the United States Department of Defense Congressionally Directed Medical Research Programs (CDMRP) as part of the agency’s call for the development of less invasive treatment technologies for cardiovascular conditions associated with cardiomyopathy.
The other half of participants received the balloon-expandable SAPIEN valve, which is made from bovine tissue and inserted inside the heartvalve by using a balloon to expand to full size. of patients who received the Evolut valve and 10.6% of those receiving the SAPIEN valve. of those receiving the SAPIEN valve.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Blood Clot 
61 
Let's personalize your content